Rallybio is a private drug discovery company. It has raised $145 million across 1 recorded round; the latest was a $145 million Series B in May 2020.
PMV mark · valuation
—
Oct 2026
Priced at
—
Total raised
$145.0M
Last round
Early Stage VC (Series B)
May 2020
Cap table — not yet on record
Rallybio's share-class structure hasn't surfaced in our sources yet. Cap tables are assembled from certificates of incorporation, round filings, and disclosures as they land.
Pro members can request priority coverage with a 48-hour turnaround.